Altered fractionation and combined radio-chemotherapy approaches: pioneering new opportunities in head and neck oncology
- 31 March 2003
- journal article
- review article
- Published by Elsevier BV in European Journal Of Cancer
- Vol. 39 (5), 560-571
- https://doi.org/10.1016/s0959-8049(02)00838-9
Abstract
Squamous cell carcinoma of the head and neck (HNSCC) are increasingly treated by multimodality approaches combining surgery, radiotherapy and chemotherapy. Randomised controlled trials have demonstrated major improvements in loco-regional tumour control from altered fractionation radiotherapy, accelerated fractionation and hyperfractionation, as compared with conventional fractionation. This experience is summarised, and the limit as to how far these modifications can be taken is discussed. It is emphasised that radiation fractionation will need to be optimised separately in multimodality strategies. Combined chemotherapy and radiotherapy has also been shown in phase III trials to produce an improved survival and an improved disease control. Chemotherapy may be given as neoadjuvant, concurrent or adjuvant treatment and the biological rationales for each of these, and the data supporting them, are reviewed. Although, large meta-analyses have shown concurrent chemoradiation to be the most effective, there is still a strong rationale for trying to develop neoadjuvant and adjuvant schedules. New, more active drugs may be important in this context. As therapy is becoming more intense, a careful recording and reporting of treatment-related morbidity is a crucial element in estimating the therapeutic gain from competing therapeutic management strategies. Development of non-cytostatic drugs and individualization of therapy using molecular prognostic markers are exciting areas of research with a great potential for improving therapy in the next decade and these are briefly discussed. Finally, a number of avenues for further research are identified.Keywords
This publication has 53 references indexed in Scilit:
- Radiotherapy-related early morbidity in head and neck cancer: quantitative clinical radiobiology as deduced from the CHART trialRadiotherapy and Oncology, 2001
- Randomized clinical trial on 7-day-continuous accelerated irradiation (CAIR) of head and neck cancer – report on 3-year tumour control and normal tissue toxicityRadiotherapy and Oncology, 2000
- A randomized study of very accelerated radiotherapy with and without amifostine in head and neck squamous cell carcinomaInternational Journal of Radiation Oncology*Biology*Physics, 2000
- Altered fractionation: limited by mucosal reactions?Radiotherapy and Oncology, 1999
- Predictive assays of radiation response in patients with head and neck squamous cell carcinoma: A review of the institute gustave roussy experienceInternational Journal of Radiation Oncology*Biology*Physics, 1997
- Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trialRadiotherapy and Oncology, 1997
- Randomized clinical trial on accelerated 7 days per week fractionation in radiotherapy for head and neck cancer. Preliminary report on acute toxicityRadiotherapy and Oncology, 1996
- Acute reaction parameters for human oropharyngeal mucosaRadiotherapy and Oncology, 1995
- Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapyRadiotherapy and Oncology, 1992
- Accelerated Fractionation in the Radiation Treatment of Head and Neck Cancer—A Critical Comparison of Different StrategiesActa Oncologica, 1988